HCW Biologics Aktie
WKN DE: A3CU4K / ISIN: US40423R1059
15.08.2025 00:33:09
|
Hcw Biologics Revenue Plunges 98 Percent
Hcw Biologics (NASDAQ:HCWB), a biotechnology company specializing in novel immunotherapies targeting age-related and inflammatory diseases, released its second quarter 2025 earnings on August 14, 2025. The most important news is an ongoing collapse in revenue, with only $6,550 (GAAP) recognized, missing analyst expectations of $7.0 million. However, the company sharply narrowed its net loss to $1.9 million (GAAP), primarily due to reduced legal expenses, down from a $15.3 million GAAP net loss in Q2 2024. Performance was mixed—cost controls and legal resolutions improved results, but revenue underperformance and continued balance sheet stress stand out as significant issues. Source: Analyst estimates for the quarter provided by FactSet. HCW Biologics develops immunotherapies aimed at treating diseases driven by chronic inflammation and immune dysfunction. Its core business utilizes two proprietary platforms: TOBI, which creates fusion-protein drugs, and TRBC, which engineers immunotherapies for cancer and autoimmune diseases.Continue readingWeiter zum vollständigen Artikel bei MotleyFool

Wenn Sie mehr über das Thema Aktien erfahren wollen, finden Sie in unserem Ratgeber viele interessante Artikel dazu!
Jetzt informieren!
Nachrichten zu HCW Biologics Inc Registered Shsmehr Nachrichten
Keine Nachrichten verfügbar. |